GH
PBYI icon

GAM Holding’s Puma Biotechnology PBYI Stock Holding History

GAM Holding’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-10,000
Closed -$874K – 827
2017
Q2 		$874K Hold
10,000
– – 0.01% 667
2017
Q1 		$372K Buy
+10,000
New +$365K 0.01% 869
2015
Q4 		– Sell
-588
Closed -$44K – 1148
2015
Q3 		$44K Hold
588
– – ﹤0.01% 1092
2015
Q2 		$69K Buy
+588
New +$106K ﹤0.01% 1094

Other funds holding PBYI

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

GAM Holding's PBYI Position: Q3 2017 in Review

GAM Holding sold out of Puma Biotechnology (PBYI) in Q3 2017, closing a stake of 10,000 shares — an estimated $874K sold.

GAM Holding first reported a position in PBYI in Q2 2015 and held it in 4 quarters. The position peaked at $874K in Q2 2017. 171 funds tracked by Wall St. Rank hold PBYI as of Q3 2017.

  • GAM Holding reported no remaining Puma Biotechnology position as of Q3 2017 after selling out during the quarter.
  • GAM Holding sold 10,000 Puma Biotechnology shares in Q3 2017, an estimated $874K.
  • GAM Holding first reported a position in Puma Biotechnology in Q2 2015 and held it in 4 quarters.
  • GAM Holding's Puma Biotechnology position peaked at $874K in Q2 2017.
  • 171 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2017.

Based on GAM Holding's 13F filing for Q3 2017, filed 14 Nov 2017.